Johnson & Johnson Innovative Medicine has taken over sales, marketing, and distribution for Remicade (infliximab) and Simponi (golimumab) in Ireland starting October 1, 2024. These drugs are used for treating inflammatory diseases like rheumatoid arthritis, ankylosing spondylitis, and juvenile arthritis. The addition of these drugs expands J&J’s immunology portfolio, which includes other therapies like Stelara and Tremfya. J&J is committed to supporting people with immune-related diseases and has launched initiatives like podcasts and a Safe Returns program. The company aims to continue research and development to help people living with immunology conditions and ensure a smooth transition for patients during the marketing and distribution change.
Source link
Johnson & Johnson Innovative Medicine expands immunology portfolio with Remicade (infliximab) and Simponi (golimumab) for treatment of Inflammatory diseases
